Profile - To The Moon

Eehui

Posts · 6Posts · 6
Following · 0Following · 0
Followers · 0Followers · 0

- EehuiEehui
  ·2021-09-01
  $Palantir Technologies Inc.(PLTR)$Upup
  263 Comment
  3
  Share
  Report
- EehuiEehui
  ·2021-08-12
  $FireEye(FEYE)$Slowly
  226 Comment
  2
  Share
  Report
- EehuiEehui
  ·2021-08-03
  Strong
  Sorry, this post has been deleted
  280 3
  7
  Share
  Report
- EehuiEehui
  ·2021-08-03
  Good
  This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine
  Pfizer might not have to wait very long for this product to hit the market.
  This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine
  178 Comment
  5
  Share
  Report
- EehuiEehui
  ·2021-08-02
  Good
  Telsa Short Squeeze? Why It’s Not Going to Happen
  TSLA stock has a large short interest, but don’t expect a short squeeze.Short squeezes have been all the rage on Wall Street in 2021. But even with its massive short interest, traders shouldn’t expect a short squeeze fromTesla. GameStop andAMC Entertainment are just two examples of stocks that skyrocketed this year thanks to short squeezes. Short sellers have always liked TSLA stock. But it takes more than just a large amount of short interest to trigger a short squeeze.The most important factor
  Telsa Short Squeeze? Why It’s Not Going to Happen
  233 2
  5
  Share
  Report
No following yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3578796920654548","uuid":"3578796920654548","gmtCreate":1615784268651,"gmtModify":1629340908450,"name":"Eehui","pinyin":"eehui","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/ab40693b6ba9d7acf5bc3c1eb1eb98ac","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":8,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":816959404,"gmtCreate":1630461986908,"gmtModify":1676530309893,"author":{"id":"3578796920654548","authorId":"3578796920654548","name":"Eehui","avatar":"https://static.tigerbbs.com/ab40693b6ba9d7acf5bc3c1eb1eb98ac","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578796920654548","idStr":"3578796920654548"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>Upup","listText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>Upup","text":"$Palantir Technologies Inc.(PLTR)$Upup","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/816959404","isVote":1,"tweetType":1,"viewCount":263,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895723543,"gmtCreate":1628774963482,"gmtModify":1676529850037,"author":{"id":"3578796920654548","authorId":"3578796920654548","name":"Eehui","avatar":"https://static.tigerbbs.com/ab40693b6ba9d7acf5bc3c1eb1eb98ac","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578796920654548","idStr":"3578796920654548"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FEYE\">$FireEye(FEYE)$</a>Slowly","listText":"<a href=\"https://laohu8.com/S/FEYE\">$FireEye(FEYE)$</a>Slowly","text":"$FireEye(FEYE)$Slowly","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/895723543","isVote":1,"tweetType":1,"viewCount":226,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807915520,"gmtCreate":1627996235860,"gmtModify":1703499302602,"author":{"id":"3578796920654548","authorId":"3578796920654548","name":"Eehui","avatar":"https://static.tigerbbs.com/ab40693b6ba9d7acf5bc3c1eb1eb98ac","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578796920654548","idStr":"3578796920654548"},"themes":[],"htmlText":"Strong&nbsp;","listText":"Strong&nbsp;","text":"Strong","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/807915520","repostId":"2156142083","repostType":2,"isVote":1,"tweetType":1,"viewCount":280,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807916699,"gmtCreate":1627996085611,"gmtModify":1703499298868,"author":{"id":"3578796920654548","authorId":"3578796920654548","name":"Eehui","avatar":"https://static.tigerbbs.com/ab40693b6ba9d7acf5bc3c1eb1eb98ac","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578796920654548","idStr":"3578796920654548"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/807916699","repostId":"2156147918","repostType":4,"repost":{"id":"2156147918","pubTimestamp":1627994460,"share":"https://ttm.financial/m/news/2156147918?lang=&edition=fundamental","pubTime":"2021-08-03 20:41","market":"us","language":"en","title":"This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2156147918","media":"Motley Fool","summary":"Pfizer might not have to wait very long for this product to hit the market.","content":"<p>In 2019 and 2020,&nbsp;<b>Pfizer</b>'s (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful product.</p>\n<p>But Prevnar 13 is no longer Pfizer's top-selling product. The COVID-19 vaccine BNT162b2, developed by Pfizer and <b>BioNTech</b> (NASDAQ:BNTX), generated sales of $7.8 billion in the first half of 2021 alone. Pfizer expects the vaccine will rake in $33.5 billion over the entire year. Even with the company splitting profits with BioNTech, Pfizer should conservatively make in the ballpark of $17 billion from BNT162b2 this year.</p>\n<p>Even more money could be on the way. Pfizer is busy working on its next potential COVID-19 blockbuster -- and it isn't a vaccine.</p>\n<p><img src=\"https://static.tigerbbs.com/2e39eb3485964eb8dab974f72921be8b\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Stopping the coronavirus in its tracks</h3>\n<p>Pfizer has stated for a while that it wouldn't restrict its efforts to fight COVID-19 to only vaccines. It has also focused on developing potential treatments for the infectious disease. The company provided an update on <a href=\"https://laohu8.com/S/AONE.U\">one</a> especially promising therapy in its second-quarter conference call last week.</p>\n<p>Protease inhibitors are a class of antiviral drugs that have been effective in treating HIV and hepatitis C. These therapies bind to protease enzymes in viruses and prevent the virus from replicating.</p>\n<p>Pfizer initiated an early stage clinical study evaluating oral protease inhibitor PF-07321332 in March of this year. The company had good news to report from that study in its Q2 update.</p>\n<p>Chief scientific officer Mikael Dolsten said that in the phase 1 study, PF-07321332 exceeded the level predicted to inhibit coronavirus viral replication by more than fivefold. Dolsten also stated that the experimental protease inhibitor showed powerful antiviral activity in preclinical testing that could be effective against \"all currently known COVID-19 variants.\"</p>\n<p>So far, the experimental antiviral drug appears to have a good safety profile. Dolsten said that there haven't been any safety issues in giving doses of up to 500 milligrams twice per day over a 10-day period.</p>\n<p>Based on these encouraging results, Pfizer advanced the oral protease inhibitor into phase 2/3 testing in July. The company will evaluate PF-07321332 in five-day and 10-day treatments for individuals who have been in close contact with someone with COVID-19.</p>\n<h3>A big market opportunity</h3>\n<p>Pfizer estimates that the addressable market for its protease inhibitor could be in the hundreds of millions of patients. That doesn't seem farfetched considering the rapid spread of COVID-19 exposure due to the delta variant.</p>\n<p>The U.S. Food and Drug Administration (FDA) has already granted Emergency Use Authorization (EUA) to <b>Regeneron</b>'s (NASDAQ:REGN) antibody cocktail REGEN-COV as a treatment for hospitalized COVID-19 patients and for post-exposure prophylaxis. However, there are a few drawbacks to Regeneron's therapy.</p>\n<p>First, REGEN-COV is expensive -- more than $2,000 per dose. Second, it must be administered via infusion or subcutaneous injection. Third, the current U.S. EUA for post-exposure prophylaxis only applies to individuals who have been exposed to COVID-19 who have a high risk of developing COVID-19 and who haven't been fully vaccinated.</p>\n<p>Pfizer's PF-07321332 would be much more convenient than REGEN-COV since it's taken orally. Although the big drugmaker hasn't given any hints about what the pricing for the antiviral therapy might be should it win EUA or approval, a lower price tag could open up a wide market that might include lower-risk individuals who are exposed to COVID-19.</p>\n<h3>Coming soon?</h3>\n<p>There shouldn't be a long wait for Pfizer's next potential COVID-19 blockbuster. Assuming the phase 2/3 testing goes well, the company thinks that it will be able to file for U.S. EUA in the fourth quarter of this year.</p>\n<p>Pfizer CEO Albert Bourla said in the company's Q2 call that he's given the green light to manufacture \"significant quantities\" of the oral protease inhibitor so that large volumes of doses will be available if EUA is granted. He added that Pfizer is absorbing the risk of making this investment because \"it is the right thing to do.\"</p>\n<p>PF-07321332 probably won't be as big a catalyst for the big pharma stock as the Pfizer-BioNTech COVID-19 vaccine. However, Pfizer won't have to split the profits on the oral therapy as it does with BNT162b2. If the company's late-stage testing of the COVID-19 drug is successful, Pfizer seems very likely to have another blockbuster on its hands in 2022.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-03 20:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In 2019 and 2020, Pfizer's (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156147918","content_text":"In 2019 and 2020, Pfizer's (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful product.\nBut Prevnar 13 is no longer Pfizer's top-selling product. The COVID-19 vaccine BNT162b2, developed by Pfizer and BioNTech (NASDAQ:BNTX), generated sales of $7.8 billion in the first half of 2021 alone. Pfizer expects the vaccine will rake in $33.5 billion over the entire year. Even with the company splitting profits with BioNTech, Pfizer should conservatively make in the ballpark of $17 billion from BNT162b2 this year.\nEven more money could be on the way. Pfizer is busy working on its next potential COVID-19 blockbuster -- and it isn't a vaccine.\n\nImage source: Getty Images.\nStopping the coronavirus in its tracks\nPfizer has stated for a while that it wouldn't restrict its efforts to fight COVID-19 to only vaccines. It has also focused on developing potential treatments for the infectious disease. The company provided an update on one especially promising therapy in its second-quarter conference call last week.\nProtease inhibitors are a class of antiviral drugs that have been effective in treating HIV and hepatitis C. These therapies bind to protease enzymes in viruses and prevent the virus from replicating.\nPfizer initiated an early stage clinical study evaluating oral protease inhibitor PF-07321332 in March of this year. The company had good news to report from that study in its Q2 update.\nChief scientific officer Mikael Dolsten said that in the phase 1 study, PF-07321332 exceeded the level predicted to inhibit coronavirus viral replication by more than fivefold. Dolsten also stated that the experimental protease inhibitor showed powerful antiviral activity in preclinical testing that could be effective against \"all currently known COVID-19 variants.\"\nSo far, the experimental antiviral drug appears to have a good safety profile. Dolsten said that there haven't been any safety issues in giving doses of up to 500 milligrams twice per day over a 10-day period.\nBased on these encouraging results, Pfizer advanced the oral protease inhibitor into phase 2/3 testing in July. The company will evaluate PF-07321332 in five-day and 10-day treatments for individuals who have been in close contact with someone with COVID-19.\nA big market opportunity\nPfizer estimates that the addressable market for its protease inhibitor could be in the hundreds of millions of patients. That doesn't seem farfetched considering the rapid spread of COVID-19 exposure due to the delta variant.\nThe U.S. Food and Drug Administration (FDA) has already granted Emergency Use Authorization (EUA) to Regeneron's (NASDAQ:REGN) antibody cocktail REGEN-COV as a treatment for hospitalized COVID-19 patients and for post-exposure prophylaxis. However, there are a few drawbacks to Regeneron's therapy.\nFirst, REGEN-COV is expensive -- more than $2,000 per dose. Second, it must be administered via infusion or subcutaneous injection. Third, the current U.S. EUA for post-exposure prophylaxis only applies to individuals who have been exposed to COVID-19 who have a high risk of developing COVID-19 and who haven't been fully vaccinated.\nPfizer's PF-07321332 would be much more convenient than REGEN-COV since it's taken orally. Although the big drugmaker hasn't given any hints about what the pricing for the antiviral therapy might be should it win EUA or approval, a lower price tag could open up a wide market that might include lower-risk individuals who are exposed to COVID-19.\nComing soon?\nThere shouldn't be a long wait for Pfizer's next potential COVID-19 blockbuster. Assuming the phase 2/3 testing goes well, the company thinks that it will be able to file for U.S. EUA in the fourth quarter of this year.\nPfizer CEO Albert Bourla said in the company's Q2 call that he's given the green light to manufacture \"significant quantities\" of the oral protease inhibitor so that large volumes of doses will be available if EUA is granted. He added that Pfizer is absorbing the risk of making this investment because \"it is the right thing to do.\"\nPF-07321332 probably won't be as big a catalyst for the big pharma stock as the Pfizer-BioNTech COVID-19 vaccine. However, Pfizer won't have to split the profits on the oral therapy as it does with BNT162b2. If the company's late-stage testing of the COVID-19 drug is successful, Pfizer seems very likely to have another blockbuster on its hands in 2022.","news_type":1},"isVote":1,"tweetType":1,"viewCount":178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":805919975,"gmtCreate":1627834432997,"gmtModify":1703496414443,"author":{"id":"3578796920654548","authorId":"3578796920654548","name":"Eehui","avatar":"https://static.tigerbbs.com/ab40693b6ba9d7acf5bc3c1eb1eb98ac","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578796920654548","idStr":"3578796920654548"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/805919975","repostId":"1169518272","repostType":4,"repost":{"id":"1169518272","pubTimestamp":1627784595,"share":"https://ttm.financial/m/news/1169518272?lang=&edition=fundamental","pubTime":"2021-08-01 10:23","market":"us","language":"en","title":"Telsa Short Squeeze? Why It’s Not Going to Happen","url":"https://stock-news.laohu8.com/highlight/detail?id=1169518272","media":"InvestorPlace\t","summary":"TSLA stock has a large short interest, but don’t expect a short squeeze.Short squeezes have been all the rage on Wall Street in 2021. But even with its massive short interest, traders shouldn’t expect a short squeeze fromTesla. GameStop andAMC Entertainment are just two examples of stocks that skyrocketed this year thanks to short squeezes. Short sellers have always liked TSLA stock. But it takes more than just a large amount of short interest to trigger a short squeeze.The most important factor","content":"<blockquote>\n <b>TSLA stock has a large short interest, but don’t expect a short squeeze.</b>\n</blockquote>\n<p>Short squeezes have been all the rage on Wall Street in 2021. But even with its massive short interest, traders shouldn’t expect a short squeeze from<b>Tesla</b>(NASDAQ:<b><u>TSLA</u></b>)</p>\n<p><b>GameStop</b>(NYSE:<b><u>GME</u></b>) and<b>AMC Entertainment</b>(NYSE:<b><u>AMC</u></b>) are just two examples of stocks that skyrocketed this year thanks to short squeezes. Short sellers have always liked TSLA stock. But it takes more than just a large amount of short interest to trigger a short squeeze.</p>\n<p>The most important factor when it comes to a short squeeze isn’t total short interest.</p>\n<p><b>Anatomy of a Short Squeeze</b></p>\n<p>It’s short percent of float. A company’s total number of existing shares are its shares outstanding. However, a significant portion of those shares outstanding are typically held by large institutional investors and company insiders. On a standard day in the market, big institutions and company executives aren’t trading millions of dollars of stock.</p>\n<p>Everyone familiar with the basics of a free market knows that price is typically determined by market supply and demand. In the stock market, the number of shares of stock is the supply side of the equation. If company insiders and institutions aren’t selling, their shares aren’t available to contribute to the available market supply.</p>\n<p>A company’s “float” represents the total shares not held by company insiders or institutions. In a practical sense, it represents the effective supply of shares available to trade freely on the market.</p>\n<p>A short squeeze is triggered in part when there is not enough supply of shares to meet demand. That dynamic sends a stock’s share price soaring. And that soaring share price triggers short sellers to cover their positions by buying stock. The more short sellers cover, the bigger the losses remaining short sellers endure.</p>\n<p>At some point, the positive feedback loop hits the point of no return and the stock takes off to the moon.</p>\n<p>Short percent of float is calculated by taking the total short interest and dividing by the total float. It’s a crude estimate of just how explosive a short squeeze could be if all the short sellers are forced to cover all at once.</p>\n<p><b>TSLA Stock vs. GameStop</b></p>\n<p>According toOrtex Analytics, TSLA stock recently had a total short interest of about 32.36 million shares. At a share price of about $645, short sellers were betting $20.87 billion against TSLA stock.</p>\n<p>GameStop recently had about 8 million shares held short, according to Ortex. At a share price of $169, that means GameStop’s total short interest was about $1.35 billion.</p>\n<p>So how is it that GME stock experienced the mother of all short squeezes back in January? Meanwhile, TSLA stock is down 4.7% year-to-date.</p>\n<p>GameStop’s short percent of float recently was about 13.3%. Any number over 10% is relatively high, but it’s nothing crazy for a company like GameStop that is struggling so badly. Tesla’s short percent of float is currently just 4.1%, which is certainly nothing extraordinary.</p>\n<p>Back on Jan. 15, GameStop’s short percent of float was an eye-popping 107.7%. That extremely high short interest coupled with the flood of Reddit traders buying the stock is the reason GME stock skyrocketed from under $20 to as high as $483 in just a couple of weeks. It was a classic short squeeze.</p>\n<p>Since that time, GameStop’s short interest and short percent of float plummeted. It’s no coincidence the stock has dropped back below $165 as well.</p>\n<p><b>What Does This Mean for Tesla?</b></p>\n<p>Yes, short sellers are betting $20.87 billion against Tesla, which is a massive amount of money. But Tesla is a $620 billion company with a huge float. It’s highly unlikely there will ever be the type of supply shortage in TSLA stock that triggered the AMC and GameStop short squeezes earlier this year.</p>\n<p>TSLA stock is not a great short squeeze candidate. Tesla is a story stock. It trades higher or lower based on the story that CEO Elon Musk and other Tesla enthusiasts spread about the company’s potential to completely take over the global auto, energy, technology and transportation industries in the long-term.</p>\n<p>When chapters get added to the story, the stock goes higher. Musk is an excellent storyteller, and he has legions of followers willing to listen to anything he says.</p>\n<p>Byalmost everyobjective fundamental valuation metric, TSLA stock is extremely overvalued. But I have always said story stocks are too dangerous to go long or short. I continue to recommend investors simply stay away from TSLA stock all together.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Telsa Short Squeeze? Why It’s Not Going to Happen</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTelsa Short Squeeze? Why It’s Not Going to Happen\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-01 10:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/07/tsla-stock-tesla-short-squeeze-why-its-not-going-to-happen/><strong>InvestorPlace\t</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>TSLA stock has a large short interest, but don’t expect a short squeeze.\n\nShort squeezes have been all the rage on Wall Street in 2021. But even with its massive short interest, traders shouldn’t ...</p>\n\n<a href=\"https://investorplace.com/2021/07/tsla-stock-tesla-short-squeeze-why-its-not-going-to-happen/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://investorplace.com/2021/07/tsla-stock-tesla-short-squeeze-why-its-not-going-to-happen/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169518272","content_text":"TSLA stock has a large short interest, but don’t expect a short squeeze.\n\nShort squeezes have been all the rage on Wall Street in 2021. But even with its massive short interest, traders shouldn’t expect a short squeeze fromTesla(NASDAQ:TSLA)\nGameStop(NYSE:GME) andAMC Entertainment(NYSE:AMC) are just two examples of stocks that skyrocketed this year thanks to short squeezes. Short sellers have always liked TSLA stock. But it takes more than just a large amount of short interest to trigger a short squeeze.\nThe most important factor when it comes to a short squeeze isn’t total short interest.\nAnatomy of a Short Squeeze\nIt’s short percent of float. A company’s total number of existing shares are its shares outstanding. However, a significant portion of those shares outstanding are typically held by large institutional investors and company insiders. On a standard day in the market, big institutions and company executives aren’t trading millions of dollars of stock.\nEveryone familiar with the basics of a free market knows that price is typically determined by market supply and demand. In the stock market, the number of shares of stock is the supply side of the equation. If company insiders and institutions aren’t selling, their shares aren’t available to contribute to the available market supply.\nA company’s “float” represents the total shares not held by company insiders or institutions. In a practical sense, it represents the effective supply of shares available to trade freely on the market.\nA short squeeze is triggered in part when there is not enough supply of shares to meet demand. That dynamic sends a stock’s share price soaring. And that soaring share price triggers short sellers to cover their positions by buying stock. The more short sellers cover, the bigger the losses remaining short sellers endure.\nAt some point, the positive feedback loop hits the point of no return and the stock takes off to the moon.\nShort percent of float is calculated by taking the total short interest and dividing by the total float. It’s a crude estimate of just how explosive a short squeeze could be if all the short sellers are forced to cover all at once.\nTSLA Stock vs. GameStop\nAccording toOrtex Analytics, TSLA stock recently had a total short interest of about 32.36 million shares. At a share price of about $645, short sellers were betting $20.87 billion against TSLA stock.\nGameStop recently had about 8 million shares held short, according to Ortex. At a share price of $169, that means GameStop’s total short interest was about $1.35 billion.\nSo how is it that GME stock experienced the mother of all short squeezes back in January? Meanwhile, TSLA stock is down 4.7% year-to-date.\nGameStop’s short percent of float recently was about 13.3%. Any number over 10% is relatively high, but it’s nothing crazy for a company like GameStop that is struggling so badly. Tesla’s short percent of float is currently just 4.1%, which is certainly nothing extraordinary.\nBack on Jan. 15, GameStop’s short percent of float was an eye-popping 107.7%. That extremely high short interest coupled with the flood of Reddit traders buying the stock is the reason GME stock skyrocketed from under $20 to as high as $483 in just a couple of weeks. It was a classic short squeeze.\nSince that time, GameStop’s short interest and short percent of float plummeted. It’s no coincidence the stock has dropped back below $165 as well.\nWhat Does This Mean for Tesla?\nYes, short sellers are betting $20.87 billion against Tesla, which is a massive amount of money. But Tesla is a $620 billion company with a huge float. It’s highly unlikely there will ever be the type of supply shortage in TSLA stock that triggered the AMC and GameStop short squeezes earlier this year.\nTSLA stock is not a great short squeeze candidate. Tesla is a story stock. It trades higher or lower based on the story that CEO Elon Musk and other Tesla enthusiasts spread about the company’s potential to completely take over the global auto, energy, technology and transportation industries in the long-term.\nWhen chapters get added to the story, the stock goes higher. Musk is an excellent storyteller, and he has legions of followers willing to listen to anything he says.\nByalmost everyobjective fundamental valuation metric, TSLA stock is extremely overvalued. But I have always said story stocks are too dangerous to go long or short. I continue to recommend investors simply stay away from TSLA stock all together.","news_type":1},"isVote":1,"tweetType":1,"viewCount":233,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":true}